CN117396474A - 血浆激肽释放酶抑制剂 - Google Patents

血浆激肽释放酶抑制剂 Download PDF

Info

Publication number
CN117396474A
CN117396474A CN202280033916.XA CN202280033916A CN117396474A CN 117396474 A CN117396474 A CN 117396474A CN 202280033916 A CN202280033916 A CN 202280033916A CN 117396474 A CN117396474 A CN 117396474A
Authority
CN
China
Prior art keywords
pyridin
mmol
formula
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033916.XA
Other languages
English (en)
Chinese (zh)
Inventor
N·帕帕约安努
J·M·特拉文斯
S·J·芬克
J·M·埃拉德
A·雷
J·A·斯宾塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN117396474A publication Critical patent/CN117396474A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202280033916.XA 2021-03-17 2022-03-16 血浆激肽释放酶抑制剂 Pending CN117396474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162477P 2021-03-17 2021-03-17
US63/162,477 2021-03-17
PCT/US2022/020479 WO2022197756A1 (en) 2021-03-17 2022-03-16 Plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
CN117396474A true CN117396474A (zh) 2024-01-12

Family

ID=81327137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033916.XA Pending CN117396474A (zh) 2021-03-17 2022-03-16 血浆激肽释放酶抑制剂

Country Status (5)

Country Link
US (1) US20240382482A1 (https=)
EP (1) EP4308228A1 (https=)
JP (1) JP2024510503A (https=)
CN (1) CN117396474A (https=)
WO (1) WO2022197756A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468232A (zh) * 1999-10-12 2004-01-14 ����˹�ж�-����˹˹������˾ 杂环钠/质子交换抑制剂和方法
US20130210805A1 (en) * 2010-10-11 2013-08-15 Robert G. Aslanian Quinazolinone-type compounds as crth2 antagonists
US20160318864A1 (en) * 2013-12-26 2016-11-03 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU2008309517B2 (en) * 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2016201052A1 (en) 2015-06-12 2016-12-15 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468232A (zh) * 1999-10-12 2004-01-14 ����˹�ж�-����˹˹������˾ 杂环钠/质子交换抑制剂和方法
US20130210805A1 (en) * 2010-10-11 2013-08-15 Robert G. Aslanian Quinazolinone-type compounds as crth2 antagonists
US20160318864A1 (en) * 2013-12-26 2016-11-03 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS: "CAS号为2393231-26-8化合物", 《STN REGISTRY数据库》, 18 December 2019 (2019-12-18), pages 2393231 - 26 *
ACS: "CAS号为2428491-72-7的化合物", 《STN REGISTRY数据库》, 18 June 2020 (2020-06-18), pages 2428491 - 72 *
MARTIN ROATSCH等: "Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases", 《FUTURE MED.CHEM.》, 14 March 2016 (2016-03-14), pages 9 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂

Also Published As

Publication number Publication date
WO2022197756A1 (en) 2022-09-22
US20240382482A1 (en) 2024-11-21
EP4308228A1 (en) 2024-01-24
JP2024510503A (ja) 2024-03-07

Similar Documents

Publication Publication Date Title
US11746120B2 (en) Stat degraders and uses thereof
US12441724B2 (en) Inhibitors of plasma kallikrein and uses thereof
JP5243970B2 (ja) タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン
EP3466929B1 (en) Heterocyclic compounds useful as pdk1 inhibitors
CN106661039B (zh) 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN117396474A (zh) 血浆激肽释放酶抑制剂
TW202246264A (zh) Tyk2抑制劑及其用途
EA036160B1 (ru) Гетероарильные соединения и их применение
US12053459B2 (en) CDK2 inhibitors and methods of using the same
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
JP2015508775A (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
IL301501B1 (en) Antiproliferation compounds and uses thereof
CN117396469A (zh) 血浆激肽释放酶的抑制剂
TW202412763A (zh) Cdk2抑制劑及使用彼等之方法
TW202519211A (zh) 經取代之胺基吡啶化合物及用其治療疾病之方法
WO2024264070A2 (en) Akt inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination